Cisplatin Dose-intensity in Testicular Cancer Treatment: Analysis of a Randomized Clinical Trial
The hypothesis that larger dose-time quotients of chemotherapy result in improved therapeutic outcome is firmly fixed in modern oncologic thought and practice. This hypothesis has enjoyed currency not only for the intuitive “rightness” of the concept, but based on the results of carefully conducted retrospective analysis of clinical trials which often demonstrate superior outcome in patients receiving more dose-intensive treatments. Unfortunately, there are only a handful of randomized prospective trials adequately testing this hypothesis.
KeywordsDose Intensity Complete Remission Rate High Dose Therapy Relative Dose Intensity Germ Cell Cancer
Unable to display preview. Download preview PDF.
- Droz, J. P., J. L Pico, M. Ghosn, M. Ostronoff, A. Azab, A. Rey, B. H. Court and M. Hayat, 1989, High Complete Remission (CR) and Survival Rates in Poor Prognosis (PP) Nonseminomatous Germ Cell Tumors (NSGCT) with High Dose Chemotherapy and Autologous Bone Marrow Transplantation (ABMT), Proc Am Soc Clin Oncol, 8: 130.Google Scholar
- Figuerado, A. T., W. M. Hryniuk, I. Strautmanis, G. Frank and S. Rendell, 1985, Cotrimazole Prophylaxis During High Dose Chemotherapy of Small Cell Lung Cancer, J Clin Oncol, 3: 54.Google Scholar
- Hortobagyi, G. N., G. P. Bodey, A. U. Buzar, D. Frye, S. Legha, R. Malik, T. L Smith, G. R. Blumenschein, H. Yap and V. Rodrriguez, 1987, Evaluation of High-Dose Versus Standard FAC Chemotherapy for Advanced Breast Cancer to Protected Environment Units: A Prospective Randomized Study, J Clin Oncol, 5: 354.PubMedGoogle Scholar
- Nichols, C. R., G. Tricot, S. D. Williams, K. van Besian, P. J. Loehrer, B. J. Roth, L Akard, R. Hoffman, R. Goulet, S. N. Wolff, L. Giannone, J. Greer, L. H. Einhorn and J. Jansen, 1989, Dose-Intensive Chemotherapy in Refractory Germ Cell Cancer-A Phase I/II Trial of High Dose Carboplatin and Etoposide with Autologous Bone Marrow Transplantation, J Clin Oncol, 7: 932.PubMedGoogle Scholar
- Sampson, M. K., S. E. Rivkin, S. E. Jones, J. J. Costanzi, A. F. LoBuglio, R. L. Stephens, E. A. Gehan and G. D. Cummings, 1984, Dose-Response and Dose-Survival Advantage for High Versus Low-Dose Cisplatin Combined with Vinblastine and Bleomycin in Disseminated Testicular Cancer A Southwest Oncology Group Study, Cancer, 53: 1029.CrossRefGoogle Scholar
- Schmoll, H. J., I. Schubert, H. Arnold, G. Dolken, T. Hecht, L. Bergmsnn, J. Illiger, U. Fink, J. Preiss, M. Dfreundschuh, H. Kaulen, B. Bonfert, A. D. Ho, C. Manegold, A. Mayr, L. Hoffmann, J. Weiss and H. Hecker, 1987, Disseminated Testicular Cancer with Bulky Disease: Results of a Phase II Study with Cisplatin Ultra High Dose/VP-16/Bleomycin, Int J Androl, 10: 311.PubMedCrossRefGoogle Scholar
- Stoter, G., D. T. Sleyfer and W. W. ten Bokkel Huinink, 1986, High Dose Versus Low Dose Vinblastine in Cisplatin-Vinbalstine Bleomycin Combination Chemotherapy of Nonseminomatous Testicular Cancer: A Randomized Study of the EORTC Genitourinary Tract Cancer Cooperative Group, J Clin Oncol, 4(8): 1199.PubMedGoogle Scholar